split-banner-image

Capecitabine

Closed

ANZ 0001: Capecitabine

BCT Study Chair:

Martin Stockler

A phase III trial to evaluate oral chemotherapy with capecitabine versus standard chemotherapy with CMF for advanced breast cancer.

international

0

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

325

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

34

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

CAPECITABINE PUBLICATIONS

2011

A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.

Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, Lord S, Friedlander M, Boyle F, Simes RJ. Breast Cancer Res Treat. 2011; 129(2):467-476, Journal

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NRC, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, and Coates AS. J Clin Oncol 2011; 29(34):4498-4504, Journal

2010

How long have I got? Estimating post-progression survivial after first line chemotherapy for metastatic breast cancer based on data from randomized trials

Kiely BE, Lee CK, Tattersall MHN, Stockler MR SABCS 2010; Poster P5-09-02, Poster

Historical cross-trial comparisons for competing treatments in advanced breast cancer – an empirical analysis of bias.

Lee CK, Lord SJ, Stockler MR, Coates AS, Gebski V, Simes RJ. Eur J Cancer 2010; 46541-548, Journal

Efficacy of first-line capecitabine 1,000mg/m2 b.i.d. in patients with metastatic breast cancer (MBC).

Robert N, Martin M, Stockler M, Kaufmann M. EBCC 2010; 478, Abstract

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.

Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ on behalf of Australian New Zealand Breast Cancer Trials Group. Br J Cancer 2010; 102(9):1341-1347, Journal

LOAD MORE

Institutions